Serious adverse events
| Mycophenolate mofetil group (n=70) | Cyclophosphamide group (n=70) | Significance | |||
| All events | Patients with ≥1 event | All events | Patients with ≥1 event | ||
| n | n (%) | n | n (%) | ||
| All serious adverse events | 73 | 35 (50) | 64 | 28 (40) | P=0.30 |
| Serious events by category | |||||
| Infections | 29 | 18 (26) | 16 | 12 (17) | P=0.30 |
| End-stage renal disease | 2 | 2 (3) | 2 | 2 (3) | P=1.0 |
| Death | 5 | 5 (7) | 4 | 4 (6) | P=1.0 |
| Malignancy | 1 | 1 (1) | 1 | 1 (1) | P=1.0 |
| Cardiovascular | 6 | 3 (4) | 6 | 5 (7) | P=0.72 |
| Disease-related events | 16 | 10 (14) | 9 | 7 (10) | P=0.61 |
| Thromboembolism | 2 | 2 (3) | 2 | 2 (3) | P=1.0 |